|Articles|June 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2001
  • Volume 0
  • Issue 0

Emotion - Biotech Renaissance Man

Author(s)Gil Bashe

The founder of five biotech companies rarely pauses, even to rest. "I can do a lot of work when the rest of my family is sleeping," he reports. "Early in the morning or late at night, there are no phones, so I needn't divert my attention." His affable tone seems contrary to the relentless drive needed to support a lifelong pursuit of excellence, but his achievements speak for themselves.

Articles in this issue

over 25 years ago

Industry Under Investigation

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

For Love of the Game

over 25 years ago

Field of Dreams

over 25 years ago

Workshop: Access Options

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

Rx-to-OTC: Unwanted Attention

over 25 years ago

Relocation: Coming to America

over 25 years ago

Stocks: Catching the Market Blues

over 25 years ago

Gathering Light

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.